Risk Factors for Severe Disease in Hospitalized Patients With COVID-19 and the Effect of Azvudine Treatment: a Retrospective Cohort Study

Fifth Affiliated Hospital, Sun Yat-Sen University

Status: Active, not recruiting

Conditions: COVID-19

Treatments: Drug: Azvudine

Study type: Observational

Funder types: Other

Identifiers

NCT06006611

ZDWY.BAS.001

Details and patient eligibility

About

The purpose of this study is to explore the factors that can affect the development of severe cases in hospitalized patients with COVID-19, including basic diseases, laboratory parameters, and clinical manifestations; In addition,to explore whether Azvudine can reduce the mortality of hospitalized patients with COVID-19.

Full description

4201 COVID-19 patients discharged from our hospital were enrolled. Binary logistic regression analysis and ROC curve were used to investigate the role of comorbidities, laboratory parameters and clinical manifestation on progression of COVID-19 patients. We used propensity-score models conditional on baseline characteristics and Univariate Cox regression model to examine whether Azvudine can reduce the mortality of COVID-19 patients.

Enrollment: 4,201 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

The COVID-19 positive patients

Exclusion criteria

1. patients treated with both azvudine and monotamivir;
2. patients receiving other antiviral drugs such as nematavir/ritonavir;
3. age < 18 years old

Trial design

4,201 participants in 3 patient groups

Azvudine group

Description:

Azvudine group included COVID-19 patients treated with azvudine antiviral therapy;

Treatment:

Drug: Azvudine

No antiviral group

Description:

No antiviral group included COVID-19 patients treated with no antiviral therapy;

Monotamivir

Description:

Monotamivir group included COVID-19 patients treated with monotamivir antiviral therapy